mRNA-1273（莫德纳）新冠疫苗接种后 Vogt-Koyanagi-Harada 病。
Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
机构信息
Department of Ophthalmology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.
出版信息
Ocul Immunol Inflamm. 2022 Jul;30(5):1250-1254. doi: 10.1080/09273948.2022.2053547. Epub 2022 Apr 11.
PURPOSE
To report a case of Vogt-Koyanagi-Harada (VKH) disease following mRNA-1273 (Moderna) COVID-19 vaccination.
METHODS
Retrospective case report.
RESULTS
A 50-year-old Korean woman developed bilateral serous retinal detachment 35 days after the first dose of COVID-19 mRNA vaccination (mRNA-1273, Moderna). She experienced adverse effects such as erythema and pain at the injection site, headache, myalgia, and allergy symptoms prior to ocular manifestation. She was diagnosed with Vogt-Koyanagi-Harada (VKH) disease. After treatment with oral prednisolone, the serous retinal detachment resolved and vision improved.
CONCLUSION
COVID-19 vaccination might be associated with VKH disease development, and the ingredients of the mRNA vaccine or viral peptide encoded by mRNA may have activated the immunological process and induced VKH disease.
目的
报告 1 例 mRNA-1273（Moderna）新冠疫苗接种后出现 Vogt-Koyanagi-Harada（VKH）病。
方法
回顾性病例报告。
结果
一名 50 岁韩国女性在接种第一剂新冠病毒 mRNA 疫苗（mRNA-1273，Moderna）后 35 天出现双侧浆液性视网膜脱离。在眼部表现之前，她出现了红斑、注射部位疼痛、头痛、肌痛和过敏症状等不良反应。她被诊断为 Vogt-Koyanagi-Harada（VKH）病。口服泼尼松龙治疗后，浆液性视网膜脱离消退，视力改善。
结论
新冠病毒疫苗接种可能与 VKH 病的发生有关，mRNA 疫苗的成分或 mRNA 编码的病毒肽可能激活了免疫过程并引发了 VKH 病。
Zotero 插件